Innovation in infectious disease therapies from immunology
- PMID: 33798650
- DOI: 10.1016/j.drudis.2021.03.023
Innovation in infectious disease therapies from immunology
Abstract
Antimicrobial therapies developed from immunology, specifically the primary function of the immune system in host defence against microbial pathogens, could offer some of the step-change strategies in drug design and development urgently required to generate much needed, truly novel interventions in infectious disease. The immune system is an as yet underexploited resource of novel molecules and the blueprints for new approaches to combating infection with non-antibiotic, directly antimicrobial strategies.
Keywords: Aminothiol; Antimicrobial peptide; Antimicrobial resistance; Antimicrobial therapy; Immunotherapy.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: D.A.O’N. is an employee, director, and shareholder of NovaBiotics and is a named inventor on all NovaBiotics patents protecting the peptide and thiol anti-infective therapies referenced in this manuscript.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources